乳腺浸润性导管癌中SATB1、NF-KB p65及HER-2蛋白的表达及其与临床病理的相关性

doi:10.3969/j.issn.1671-7171.2021.06.012

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (1747 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression patterns of Special AT-rich binding protein 1(SATB1), nuclear factor-kappa B p65(NF-κB p65) and HER-2 in invasive ductal breast carcinoma, and their correlation with the clinical and pathological Parameters.【Methods】The protein expression of SATB1, NF-κB p65 and HER-2 were examined by immunohistochemistry, and fluorescence in situ hybridization (FISH) was employed to detect HER2 amplification. 【Results】The expression rates of SATB1, NF-κB p65 and HER-2 in 90 cases of invasive ductal breast carcinoma were 71%(64/90), 53.3%(48/90) and 30%(27/90) respectively, and higher in comparison to normal breast tissues. The expression of SATB1 and NF-κB p65 were correlated with tumor size, histological classification, TNM stage, lymph node metastasis and ER status, and not associated with age. The over-expression of HER-2 was only correlated with lymph node metastasis, but not associated with tumor size, histological classification, TNM stage, ER status and age. The positive correlation was found between the expression of SATB1 and NF-κB, but HER2 expression was not significantly correlated with that of other proteins. 【Conclusion】The expression of SATB1 and NF-κB were closely correlated with clinical and pathological parameters of invasive ductal breast carcinoma, and may have synergistic effect in during the occurrence and development of breast carcinoma. The expression of SATB1 and NF-κB may be used as prognostic biomarkers of invasive ductal breast carcinoma.

Key words： Breast Neoplasms/PA Neoplasm Proteins Transcription Factor RelA Receptor, ErbB-2 Prognosis

Received: 06 May 2021

PACS:

R737.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wen-zhong
	LI Yu-hui
	TAN Bing

Cite this article:

WANG Wen-zhong,LI Yu-hui,TAN Bing. SATB1, NF-κB and HER-2 Expression Patterns in Invasive Ductal Breast Carcinoma and Their Correlation with Clinical and Pathological Parameters[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 846-850.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.06.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I6/846

[1] JEMAL A, BRAY F, CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011, 61(2):69-90.
[2] ALVAREZ J D, YASUI D H, NIIDA H, et al.The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development[J].Genes Dev,2000, 14(5):521-535.
[3] HAN HJ, RUSSO J, KOHWI Y, et al.SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis[J].Nature,2008, 452(7184):187-193.
[4] CHEN F, CASTRANOVA V, SHI X, et al.New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases[J].Clin Chem,1999, 45(1):7-17.
[5] CHEN F, CASTRANOVA V, SHI X.New insights into the role of nuclear factor-kappaB in cell growth regulation[J].Am J Pathol,2001, 159(2):387-397.
[6] MERKHOFER E C, COGSWELL P, BALDWIN A S.Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha[J].Oncogene,2010, 29(8):1238-1248.
[7] QIU J, WANG X, GUO X,et al.Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines[J].Oncol Rep,2009, 22(4):935-941.
[8] ROSKOSKI R JR.The ErbB/HER family of protein-tyrosine kinases and cancer[J].Pharmacol Res,2014, 79:34-74.
[9] IQBAL N, IQBAL N.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers:Overexpression and Therapeutic Implications[J].Mol Biol Int,2014,852748.
[10] REMMELE W, STEGNER H E.Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue[J].Pathologe,1987,8(3):138-140.
[11] XU L, DENG H X, XIA J H, et al.Assignment of SATB1 to human chromosome band 3p23 by in situ hybridization[J].Cytogenet Cell Genet,1997, 77(3-4):205-206.
[12] GUO L, ZHENG J, YU T, et al.Elevated expression of SATB1 is involved in pancreatic tumorigenesis and is associated with poor patient survival[J].Mol Med Rep,2017,16(6):8842-8848.
[13] GLATZEL-PLUCI SKA N, PIOTROWSKA A, DZI GIEL P, et al.The role of SATB1 in tumour progression and metastasis[J].Int J Mol Sci,2019, 20(17):E4156.
[14] FRÖMBERG A, ENGELAND K, AIGNER A.The Special AT-rich sequence binding protein 1 (SATB1) and its role in solid tumors[J].Cancer Lett,2018, 417:96-111.
[15] IORNS E, HNATYSZYN H J, SEO P, et al.The role of SATB1 in breast cancer pathogenesis[J].J Natl Cancer Inst,2010, 102(16):1284-1296.
[16] 赵莉娟,白中红,许软成.乳腺癌患者核基质结合区结合蛋白1和核因子相关蛋白κB的表达水平及其相关性分析[J].癌症进展,2018,16(3):324-327.
[17] ORDINARIO E, HAN H J, FURUTA S, et al.ATM suppresses SATB1-induced malignant progression in breast epithelial cells[J].PLoS One,2012, 7(12):e51786.
[18] LEVIDOU G, KORKOLOPOULOU P, NIKITEAS N, et al.Expression of nuclear factor kappaB in human gastric carcinoma:relationship with I kappaB a and prognostic significance[J].Virchows Arch,2007,450(5):519-527.
[19] SMOLI SKA M, GRZANKA D, ANTOSIK P, et al.HER2, NF-κB, and SATB1 expression patterns in gastric cancer and their correlation with clinical and pathological parameters[J].Dis Markers,2019, 2019:6315936.
[20] BISWAS D K, SHI Q, BAILY S,et al.NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis[J].Proc Natl Acad Sci USA,2004, 101(27):10137-10142.
[21] ZANG Y Q, FENG Y Y, LUO Y H, et al.Quinalizarin induces ROS mediated apoptosis via the MAPK, STAT3 and NFκB signaling pathways in human breast cancer cells[J].Mol Med Rep,2019, 20(5):4576-4586.
[22] CHEN C, YANG J M, HU T T, et al.Prognostic role of human epidermal growth factor receptor in gastric cancer:a systematic review and meta-analysis[J].Arch Med Res,2013, 44(5):380-389.
[23] BEGNAMI M D, FUKUDA E, FREGNANI J H,et al.Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas:HER2 and HER3 are predictors of poor outcome[J].J Clin Oncol,2011, 29(22):3030-3036.
[24] JANJIGIAN Y Y, WERNER D, PAULIGK C, et al.Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status:a European and USA International collaborative analysis[J].Ann Oncol,2012, 23(10):2656-2662.
[25] GÓ MEZ-MARTIN C, GARRALDA E, ECHARRI M J, et al.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer[J].J Clin Pathol,2012, 65(8):751-757.
[26] ARIGA R, ZARIF A, KORASICK J, et al.Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma[J].Breast J,2005, 11(4):278-280.
[27] KUSTIC D, LOVASIC F, BELAC-LOVASIC I, et al.Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma[J].Rev Med Chil,2019, 147(5):557-567.
[28] LI Q Q, CHEN Z Q, XU J D, et al.Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells[J].Cancer Sci,2010, 101(1):80-86.
[29] LIU X, ZHENG Y, QIAO C, et al. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics[J].Diagn Pathol,2015, 10:50.
[30] BAILEY S T.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth[J].Mol Cancer Res,2014, (3):408-420.